Literature DB >> 29192315

Clinical Factors Associated With Reoperation and Prolonged Length of Stay in Free Tissue Transfer to Oncologic Head and Neck Defects.

William W Thomas1, Jason Brant1, Jinbo Chen2, Orly Coblens3, John P Fischer4, Jason G Newman1, Ara A Chalian1, Rabie M Shanti1, Steven B Cannady1.   

Abstract

IMPORTANCE: Prolonged hospitalization and reoperation after free tissue transfer may be associated with certain clinical factors.
OBJECTIVE: To determine patient and surgical factors associated with length of stay (LOS) and reoperation following surgical procedures for malignant neoplasm of the head and neck involving microvascular free tissue transfer reconstruction. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective review of American College of Surgeons National Surgical Quality Improvement Program data from 2012 to 2014 using International Classification of Diseases, Ninth Revision (ICD-9), codes for malignant neoplasms of the head and neck. Multivariable logistic regression modeling was used to examine correlation of patient and surgical variables with reoperation and LOS. The national retrospective database included outcomes from community and academic participant hospitals (517 member institutions in 2014). A total of 1115 cases of head and neck malignant neoplasm ablation with microvascular free tissue transfer flap were reviewed retrospectively. MAIN OUTCOMES AND MEASURES: Incidence of reoperation within 30 days of index operation and hospitalization equal to or longer than 13.0 days, which is equal to being in the top quartile for duration of stay.
RESULTS: Of the 1115 patients, 370 (33.2) were female, and the mean (SD) age was 66.8 (3.9) years. Predictors of prolonged length of stay included return to the operating room (odds ratio [OR], 4.8; 95% CI, 3.3-6.9), smoking (OR, 2.1; 95% CI, 1.5-3.1), clean-contaminated wound (OR, 2.2; 95% CI, 1.3-4.0), bony flap (OR, 1.8; 95% CI, 1.2-2.8), age (OR, 1.5; 95% CI, 1.2-1.7), and operative time (OR, 1.2; 95% CI, 1.1-1.3). Reoperation occurred 298 times for 225 patients (20.2%). Mean (SD) time to reoperation was 8.0 (7.7) days, with 180 (80%) occurring before discharge from the primary operation. The most common indications for reoperation were neck exploration (37 [12.4%]) or incision and drainage of neck (35 [11.7%]). CONCLUSIONS AND RELEVANCE: American College of Surgeons National Surgical Quality Improvement Program data allow for large database analysis of free flap transfer to the head and neck. The data herein provide information to help guide surgeons on which patients will require longer stay in hospital and the most common reasons for return to the operating room. Wound class of index operation, subsequent wound-related complications, and long duration of the index operation were the primary drivers of increased risk for reoperation and, therefore, prolonged hospitalization. These same factors were also associated with prolonged hospitalization without reoperation. LEVEL OF EVIDENCE: NA.

Entities:  

Mesh:

Year:  2018        PMID: 29192315      PMCID: PMC5885965          DOI: 10.1001/jamafacial.2017.1771

Source DB:  PubMed          Journal:  JAMA Facial Plast Surg        ISSN: 2168-6076            Impact factor:   4.611


  19 in total

1.  How slow is too slow? Correlation of operative time to complications: an analysis from the Tennessee Surgical Quality Collaborative.

Authors:  Brian J Daley; William Cecil; P Chris Clarke; Joseph B Cofer; Oscar D Guillamondegui
Journal:  J Am Coll Surg       Date:  2015-01-09       Impact factor: 6.113

2.  Analysis of 49 cases of flap compromise in 1310 free flaps for head and neck reconstruction.

Authors:  Peirong Yu; David W Chang; Michael J Miller; Gregory Reece; Geoffrey L Robb
Journal:  Head Neck       Date:  2009-01       Impact factor: 3.147

3.  The role of the implantable Doppler probe in free flap surgery.

Authors:  Mark K Wax
Journal:  Laryngoscope       Date:  2014-03       Impact factor: 3.325

4.  Does surgical quality improve in the American College of Surgeons National Surgical Quality Improvement Program: an evaluation of all participating hospitals.

Authors:  Bruce L Hall; Barton H Hamilton; Karen Richards; Karl Y Bilimoria; Mark E Cohen; Clifford Y Ko
Journal:  Ann Surg       Date:  2009-09       Impact factor: 12.969

5.  Use of free tissue transfer in head and neck cancer surgery and risk of overall and serious complication(s): An American College of Surgeons-National Surgical Quality Improvement Project analysis of free tissue transfer to the head and neck.

Authors:  Steven B Cannady; Kyle M Hatten; Andres M Bur; Jason Brant; John P Fischer; Jason G Newman; Ara A Chalian
Journal:  Head Neck       Date:  2016-12-21       Impact factor: 3.147

6.  Who pays for poor surgical quality? Building a business case for quality improvement.

Authors:  Justin B Dimick; William B Weeks; Raj J Karia; Smita Das; Darrell A Campbell
Journal:  J Am Coll Surg       Date:  2006-06       Impact factor: 6.113

7.  Cost-effectiveness of microsurgical reconstruction for head and neck defects after oncologic resection.

Authors:  Lin Lin Gao; Marten Basta; Suhail K Kanchwala; Joseph M Serletti; David W Low; Liza C Wu
Journal:  Head Neck       Date:  2016-11-29       Impact factor: 3.147

8.  Octogenarian free flap reconstruction: complications and cost of therapy.

Authors:  Keith E Blackwell; Babak Azizzadeh; Carlos Ayala; Jeffrey D Rawnsley
Journal:  Otolaryngol Head Neck Surg       Date:  2002-03       Impact factor: 3.497

9.  An analysis of early oncologic head and neck free flap reoperations from the 2005-2012 ACS-NSQIP dataset.

Authors:  Cassandra A Ligh; Jonas A Nelson; Jason D Wink; Patrick A Gerety; John P Fischer; Liza C Wu; Suhail K Kanchwala
Journal:  J Plast Surg Hand Surg       Date:  2015-11-16

10.  Impact of patient comorbidities on head and neck microvascular reconstruction. A report on 423 cases.

Authors:  Clair Vandersteen; Olivier Dassonville; Emmanuel Chamorey; Gilles Poissonnet; Eric Edi Martial Nao; Cédric Sandy Pierre; Axel Leyssale; Frédéric Peyrade; Marie Noelle Falewee; Anne Sudaka; Juliette Haudebourg; François Demard; José Santini; Alexandre Bozec
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-19       Impact factor: 2.503

View more
  6 in total

1.  Current practices in microvascular reconstruction in otolaryngology-head and neck surgery.

Authors:  Kevin J Kovatch; John E Hanks; Jayne R Stevens; Chaz L Stucken
Journal:  Laryngoscope       Date:  2018-09-08       Impact factor: 3.325

2.  How Much Blood Could a JP Suck If a JP Could Suck Blood?

Authors:  Erin M Mamuyac; Andrew K Pappa; Brian D Thorp; Charles S Ebert; Brent A Senior; Adam M Zanation; Feng-Chang Lin; Adam J Kimple
Journal:  Laryngoscope       Date:  2018-12-13       Impact factor: 3.325

3.  Reconstruction with Free Flaps of Head and Neck Cancer Defects: A National Cohort Study.

Authors:  Giancarlo Buitrago; Felipe Caballero; Giovanni E Montealegre
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-08-19

4.  Unplanned reoperation after radical surgery for oral cancer: an analysis of risk factors and outcomes.

Authors:  Wei Zhang; Hong Zhu; Pu Ye; Meng Wu
Journal:  BMC Oral Health       Date:  2022-05-25       Impact factor: 3.747

5.  Development and Validation of Nomograms for Predicting Delayed Postoperative Radiotherapy Initiation in Head and Neck Squamous Cell Carcinoma.

Authors:  Dylan A Levy; Hong Li; Katherine R Sterba; Chanita Hughes-Halbert; Graham W Warren; Brian Nussenbaum; Anthony J Alberg; Terry A Day; Evan M Graboyes
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-05-01       Impact factor: 6.223

6.  Transoral robotic surgery in head and neck district: a retrospective study on 67 patients treated in a single center.

Authors:  Fraco Ionna; Agostino Guida; Luigi Califano; Gaetano Motta; Giovanni Salzano; Ettore Pavone; Corrado Aversa; Francesco Longo; Salvatore Villano; Ludovica Marcella Ponzo; Pierluigi Franco; Simona Losito; Franco Maria Buonaguro; Maria Lina Tornesello; Maria Grazia Maglione
Journal:  Infect Agent Cancer       Date:  2020-06-15       Impact factor: 2.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.